Showing results (31-40 of 251) with videos related to

Sort By:
Pageof 26
Nutrition and Cancer|January 29, 2019
Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance StatusTakayuki Fujio, Kazuhisa Nakashima, Tateaki Naito, et al.
Virchows Archiv : an International Journal of Pathology|January 22, 2011
MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinomaKyoichi Kaira, Haruyasu Murakami, Masakuni Serizawa, et al.
Medical Oncology (Northwood, London, England)|September 28, 2011
Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinomaKyoichi Kaira, Yasuhisa Ohde, Kazuo Nakagawa, et al.
International Journal of Surgical Pathology|November 24, 2011
Depolarized MUC1 expression is closely associated with hypoxic markers and poor outcome in resected non-small cell lung cancerKyoichi Kaira, Kazuo Nakagawa, Yasuhisa Ohde, et al.
Cancer Medicine|March 6, 2021
Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumorsYutaka Fujiwara, Hirotsugu Kenmotsu, Noboru Yamamoto, et al.
Anticancer Research|February 6, 2009
Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimensSatoshi Igawa, Toshiaki Takahashi, Yukiko Nakamura, et al.
Lung Cancer (Amsterdam, Netherlands)|April 21, 2015
Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancerMakoto Nishio, Atsushi Horiike, Haruyasu Murakami, et al.
Anticancer Research|July 1, 2015
Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional StudyYasunori Enomoto, Hirotsugu Kenmotsu, Naohiro Watanabe, et al.
Japanese Journal of Clinical Oncology|March 24, 2022
The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance studyYuichiro Ohe, Naoya Yamazaki, Nobuyuki Yamamoto, et al.
Respirology (Carlton, Vic.)|May 26, 2017
Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non-small cell lung cancerHaruki Kobayashi, Shota Omori, Kazuhisa Nakashima, et al.
Pageof 26